AstraZeneca’s PACIFIC-2 Phase 3 trial for Imfinzi in NSCLC falls short of primary endpoint
In the latest development in oncology research, AstraZeneca's PACIFIC-2 Phase III trial, involving Imfinzi (durvalumab) concurrently administered with platinum-based chemoradiotherapy (CRT), did not achieve statistical ... Read More
AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study
AstraZeneca's IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (HCC), according to the ... Read More
AstraZeneca reports positive results for phase 2 COAST trial of oleclumab and monalizumab
AstraZeneca has reported positive results from the COAST phase 2 trial of its oleclumab or monalizumab in combination with Imfinzi (durvalumab) in patients with non-small ... Read More
AstraZeneca’s Imfinzi garners positive opinion from CHMP for NSCLC treatment
AstraZeneca has reached a crucial milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a ... Read More
FDA removes clinical hold on Advaxis’ Axalimogene Filolisbac, Durvalumab combo trial
Advaxis, a biotech firm based in New Jersey, announced a significant regulatory update as the U.S. Food and Drug Administration (FDA) has lifted the clinical ... Read More